Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specialized in life sciences technology transfer and collaborative research projects funding. It works under a Public Service Concession Agreement (CSP).

0

patent families*

0

number of contracts and licenses*

* For the year 2023

0

millions of euros invested in Proof of concept

0

projects detected*

Serving research

The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological research to clinical development, with the aim of creating economic and societal value.

News
Event

Inserm Transfert est partenaire de la 10ème journée du SNITEM le 17

Inserm Transfert est partenaire de la 10ème journée start-up innovante du dispositif médical du SNITEM le 17 juin prochain à la Cité des Sciences et de l'industrie. En plénière " 2 questions à Pascale Augé ", Présidente du Directoire ...

//
Event

Inserm Transfert at BIO International Convention Boston, June 16-19

Noémie Pellegrin, Directrice Partenariats Industriels & Entrepreneuriat et Aymeric Empereur, Senior Business ...

16/06/2025
Event

Congrès C.U.R.I.E 2025

Inserm Transfert participera au Congrès C.U.R.I.E du 2 au 4 juin au Palais des Congrès de Bordeaux ! Cette année, ...

03/06/2025
Event

Journée de la Recherche Clinique : focus sur l’essai ANRS ELDORADO

En cette journée de la Recherche Clinique, focus sur l’essai ANRS ELDORADO portant sur le VIH. Un essai clinique ...

//

Quick access

  • Inserm Transfert
  • Industrial Partnerships
  • Collaborative projects
  • Event

You are

Collaborative projects

High-quality support for a research excellence.

SOLVE

Horizon Europe

Decoding immunity to address SARS-CoV-2 challenges. Despite the swift development of SARS-CoV-2 vaccines, the pandemic persists due to emerging variants and waning immunity. In this context, the ...

IMPROVE PRETERM

Horizon Europe

Taking care of very preterm infants. Each year, over 50 000 infants are born very preterm (before 32 weeks of gestation) in Europe and face lifelong challenges such as cognitive impairment, ...

INVENTS

Horizon Europe

The evaluation of new medicines for rare diseases is challenging for several reasons, among which are the small patient sample sizes, heterogeneity of patients and diseases and heterogeneity in ...

HT-ADVANCE

Horizon Europe

HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification biomarkers as companion diagnostics for the prescription of ...

MPX-RESPONSE

Horizon Europe

The aims of the MPX-RESPONSE project were to enhance understanding of mpox (Monkeypox), evaluate potential treatments, and bolster Europe's preparedness for emerging infectious disease outbreaks. The ...

ARTIDe

Horizon Europe

ARTiDe aims to develop a new antigen-specific immunotherapy for type 1 diabetes, via genetic engineering, using patients' regulatory T lymphocytes (Treg) to express an autoreactive T lymphocyte ...

MITI2

Horizon Europe

Inflammatory bowel disease (IBD) refers to a group of chronic conditions that cause inflammation in the digestive tract. IBD requires long-term management and treatment, which includes medication, ...

OBELISK

Horizon Europe

The Obelisk project consists of developing tools for predicting obesity during the first 1,000 days of life and testing innovative prevention programs, particularly among adolescents, in several ...

BE READY

Horizon Europe

European partnership for pandemic preparedness The COVID-19 pandemic has taught us that planning and investing in research and innovation well before a health crisis occurs is crucial in predicting ...

ISIDORe

Horizon Europe

The ISIDORe project assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials. ...

CARE-IN-HEALTH

Horizon Europe

Cardiovascular disease prevention through an immunological blueprint Epidemiological evidence suggests an association between chronic inflammation and risk for cardiovascular disease (CVD). ...

INTERCEPT-T2D

Horizon Europe

Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous ...

HERVCOV

Horizon Europe

The HERVCOV project aims to analyze the role of human endogenous retroviruses (HERVs), known for their high pro-inflammatory potential, in the immunopathogenesis of COVID-19 and its long-term ...

REGERNA

Horizon Europe

The main aim of the REGeRNA project is to develop a synthetic messenger RNA capable of reinducing cardiomyocyte proliferation in patients suffering from heart failure. Heart failure (HF) is a major ...

RITA-MI 2

H2020

RITA-MI 2 will conduct a phase 2b randomised double-blind placebo-controlled CT to assess the impact of B cell depletion with the CD20 mAb rituximab on left ventricular dysfunction and cardiac ...

CBIG-SCREEN

H2020

CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and underused ...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS) ...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016. Kidney transplantation is currently the best therapeutic option with around 1,500,000...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to provide ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and is...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune ...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

PREVAC-UP

EDCTP

The project PREVAC-UP is built around the PREVAC consortium. Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and cellular immune...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and reduce ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of ...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear later...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that ...

EU-RESPONSE

H2020

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and ...